‍Medically reviewed by Michelle Forcier, MD, MPH — Licensed in Massachusetts  |  Last reviewed: March 2026

For most people, yes — HRT is safe and is the most effective treatment available for menopause symptoms. Decades of fear about HRT were driven by a misread of a single 2002 study. Current evidence supports HRT as low-risk for healthy people who start it within 10 years of menopause or before age 60.

If you’ve heard that hormone replacement therapy is dangerous, you’re not alone — and you’ve been misled by one of the most consequential misinterpretations in modern medical history. The 2002 Women’s Health Initiative study scared millions of people away from effective treatment. The researchers themselves later clarified that the original findings were misapplied. Twenty-plus years of subsequent research has built a much clearer picture.

Here’s what we actually know.

What happened with the 2002 study?

In 2002, the Women’s Health Initiative (WHI) published findings that HRT increased the risk of breast cancer, heart disease, stroke, and blood clots. HRT prescriptions plummeted almost overnight. Many providers stopped offering it entirely.

The problem: the study’s findings were widely overstated and misapplied to the wrong population.

The WHI studied older women — average age 63 — many of whom started HRT more than 10 years after menopause. The risks associated with HRT in that population don’t apply to healthier, younger people starting HRT closer to the onset of menopause. When researchers re-analyzed the data by age group, the picture looked dramatically different. For women in their 50s who started HRT shortly after menopause, there was no increased mortality — and in some analyses, a reduced risk of cardiovascular disease.

The WHI also used a specific oral synthetic progestin (medroxyprogesterone acetate) that has since been found to carry more risk than the oral bioidentical progesterone commonly used today. The type of hormone matters.

The short version: the study that scared people away from HRT was studying the wrong population, using older formulations, and its findings were misapplied to people it was never designed to represent. The field has substantially moved on.

What does current evidence say about HRT safety?

Current evidence, including updated guidance from the Menopause Society (formerly NAMS), the British Menopause Society, and the European Menopause and Andropause Society, supports the following:

• For most healthy people who start HRT within 10 years of menopause or before age 60, the benefits outweigh the risks.
• HRT does not increase mortality for most people in the appropriate timing window. Some analyses show reduced all-cause mortality for people who start early.
• Estrogen-only HRT (for people without a uterus) has a favorable safety profile, with some evidence suggesting reduced cardiovascular and breast cancer risk compared to combination therapy.
• Transdermal estrogen (patch, gel, cream) carries lower clot risk than oral estrogen, because it bypasses first-pass liver metabolism.
• Oral micronized progesterone (bioidentical) is associated with lower breast cancer and cardiovascular risk than the synthetic progestin used in the original WHI study.
• Local vaginal estrogen — used for genitourinary symptoms — has minimal systemic absorption and is considered very low risk, including for people with a history of breast cancer in many clinical contexts.

The timing window: The evidence for HRT’s safety and benefit is strongest for people who begin within 10 years of menopause onset (generally before age 60). Starting HRT for the first time later than that is a different clinical conversation. This is called the “window of opportunity” or the timing hypothesis.

What are the real risks of HRT?

HRT is not risk-free. Being honest about what the risks actually are — rather than dismissing them or catastrophizing them — is what good care looks like.

Breast cancer

This is the risk that most people are thinking about. The picture is more nuanced than most people realize.

Estrogen-only HRT has not been shown to increase breast cancer risk, and some studies suggest it may modestly reduce it. Combination HRT (estrogen plus progestins) is associated with a small increased risk for long-term use, particularly beyond 5 years. That risk is comparable to the increased risk associated with having one glass of wine per day, or a BMI over 30. The type of progestogen matters: oral micronized progesterone appears to carry less risk than synthetic progestins.

If you have a personal history of breast cancer, HRT requires a more individualized conversation with your provider — it’s not automatically off the table, but it needs careful evaluation.

Blood clots (venous thromboembolism)

The relative risk for blood clots can increase in people who use oral estrogens. Oral estrogens are linked to a 2-4 fold increase in risk of blood clots, with an absolute risk in blood clots associated with estrogen therapies of 1 in 300 patients per year. To keep this risk in perspective, there are millions of healthy pregnancies every day, but the risk for blood clots during pregnancy may increase 5 fold (and as high as 20 fold during the first trimester and immediately after delivery). 

The hormone currently recommended in both gender affirming and menopausal hormone therapies is 17B estradiol. This hormone formulation seems to offer lower risk than older estrogen formulations. 

In fact, transdermal 17B estradiol, or estradiol delivered through the skin to the blood stream, using a patch, cream or gel, does not currently appear to have any increase in blood clot risk whatsoever.

Stroke

Oral estrogen is associated with a small increased stroke risk. Transdermal estrogen is not. For most healthy people in the timing window, the absolute risk increase is very small. People with a history of stroke or TIA should discuss HRT carefully with their provider. People taking anti-coagulation therapies according to recommendations are candidates for estradiol therapy.

Cardiovascular disease

Estrogen started close to menopause (within the timing window) appears to be cardioprotective for most people — it helps maintain favorable cholesterol levels and arterial function. Starting HRT more than 10 years after menopause in people who already have cardiovascular disease is the context in which risk increases. Timing matters enormously here. Additional health factors such as high blood pressure and cholesterol, diabetes, sleep apnea and others significantly add to cardiovascular and stroke risk.

Who is HRT appropriate for?

HRT is appropriate for most people who:

• Are experiencing significant menopause symptoms that are affecting quality of life
• Start during early menopause and are within 10 years of menopause onset or under age 60
• Do not have specific contraindications (listed below)
• Have been evaluated by a knowledgeable provider and want to treat their symptoms

‍

HRT is also the most effective prevention for two significant long-term menopause health risks: osteoporosis and cardiovascular changes associated with estrogen decline. While HRT is not recommended as a primary treatment for these, this is worth factoring into the conversation, in addition to symptom relief.

Who should be cautious about or avoid HRT?

HRT may not be appropriate — or may require a more careful individualized assessment — for people with:

• A personal history of hormone-receptor-positive breast cancer (requires specialist input; not automatically excluded)
• A history of blood clots or clotting disorders (transdermal estrogen may still be an option)
• A history of stroke or TIA
• Uncontrolled high blood pressure
• Active severe liver disease or failure
• Unexplained vaginal bleeding (requires evaluation first)

‍

This is not a definitive exclusion list — it’s a list of factors your FOLX clinician will want to review carefully with you. Many people with one or more of these factors can still use some form of HRT, particularly transdermal formulations or local vaginal estrogen. The conversation matters more than the checklist.

If you’ve been told you can’t have HRT: Ask your provider to walk through the specific reason. Many people were told they can’t have HRT based on outdated guidance or overly cautious interpretation of the original WHI data. It’s worth revisiting with a provider who is current on the evidence.

What HRT does FOLX prescribe?

FOLX offers a full range of evidence-based hormone therapy for menopause:

Systemic estrogen

For hot flashes, night sweats, sleep disruption, mood changes, brain fog, and bone health. Available as:

• Oral estrogen
• Transdermal patch, gel, or cream (preferred for people with elevated clot or stroke risk)
• Systemic estrogen ring

Progesterone

Required for anyone with a uterus taking systemic estrogen, to protect the uterine lining from precancerous endometrial hyperplasia. FOLX prescribes oral micronized progesterone — the bioidentical form with a more favorable safety profile than older synthetic progestins.

Local vaginal estrogen

For genitourinary symptoms (vaginal dryness, discomfort during sex, urinary urgency). Minimal systemic absorption. Considered low-risk and can be used independently of systemic HRT, or alongside it. Low doses of vaginal estradiol do not necessarily require additional oral progestin use. 

Testosterone

Transdermal testosterone gel or cream for low libido when HRT alone is not effective. Testosterone for menopause is considered “off-label” in the US, as are many hormone medications. Vaginal testosterone for vaginal atrophy symptoms. 

Note: FOLX does NOT prescribe injectable estradiol or injectable testosterone as part of menopause care. Injectable testosterone or estradiol may be prescribed when it’s also part of treatment for gender dysphoria or gender-related goals.

What if HRT isn’t right for me?

Non-hormonal options exist and work. FOLX recommends a healthy lifestyle and activities, such as regular lifestyle, stress reduction, healthy sleep and diet along with limited caffeine and alcohol intake. FOLX may prescribe additional medications including:

• Selective serotonin reuptake inhibitors (SSRIs) such as Paroxetine approved for vasomotor symptoms (hot flashes, night sweats) and Citralopram (vasomotor and mood symptoms)
• Veozah (fezolinetant) — a newer non-hormonal medication that targets the neural pathway driving hot flashes at the source
• Gabapentin — effective for night sweats and sleep disruption

For genitourinary symptoms specifically, local vaginal estrogen is often considered even when systemic HRT isn’t appropriate, given its minimal systemic absorption. It’s worth discussing as a standalone option.

What’s specific about HRT safety for LGBTQ+ people?

This is an area where mainstream menopause content consistently falls short. A few things worth naming:

Provider bias and undertreated menopause

Research consistently shows that lesbian, bisexual, and queer cis women use HRT at lower rates than heterosexual women — not because of different medical needs or preferences, but because of healthcare avoidance, provider mistrust, and lack of affirming options. If you’ve been managing symptoms without treatment because seeking care felt like too much work, that’s a structural problem in healthcare, not a personal choice you’re stuck with.

Trans men and transmasculine people

If you’ve been on testosterone therapy and still have ovaries, you may still experience menopause. Testosterone can suppress menstrual cycles and reduces estradiol and progesterone production, but doesn’t necessarily eliminate all the hormonal changes during aging and menopause. The interaction between testosterone therapy and menopause is an area where FOLX clinicians have specific experience — it’s not a conversation most mainstream menopause providers are equipped to have.

If you’ve stopped testosterone or if you’re approaching menopause age, it’s worth having a direct conversation about whether you’re experiencing perimenopause symptoms and what treatment options fit your goals and your body.

People who have had gender-affirming surgery

Oophorectomy as part of gender-affirming care causes surgical menopause — an abrupt hormonal drop rather than a gradual transition. Symptoms are often more intense and immediate. If you’ve had an oophorectomy and aren’t on any hormone replacement, this is worth discussing with a provider. It is currently not medically recommended to have no gender hormones in early or mid adulthood given possible impact on bone density and other health risks. The considerations are different from older persons experiencing natural menopause.

FOLX clinicians understand LGBTQ+ health contexts. You won’t have to spend your appointment explaining why inclusive care matters before we can talk about your hot flashes.

Get started with FOLX menopause care → folxhealth.com/get-started

Frequently Asked Questions

Is HRT safe for long-term use?

For most people, yes. Current evidence supports continued use beyond 5 years for people whose symptoms warrant it and who don’t have specific risk factors. The guidance that HRT should only be used “short-term” came from incorrect interpretations of data. Your clinician should reassess your situation annually — but “time’s up” is not a valid reason to stop if treatment is still benefiting you and your risk profile is stable.

Does HRT cause breast cancer?

Estrogen-only HRT has not been shown to increase breast cancer risk and may modestly reduce it. Combination HRT (estrogen plus progestogen) is associated with a small increased risk with long-term use, comparable in magnitude to the risk increase from daily alcohol use. The type of progestogen matters — oral micronized progesterone carries less risk than older synthetic progestins. If you have a personal history of breast cancer, this requires an individualized conversation, not a blanket no.

What’s the safest form of HRT?

Transdermal estrogen (patch, gel, or cream) is generally preferred over oral estrogen because it bypasses liver metabolism and doesn’t carry the same small increased risk of blood clots or stroke. Oral micronized progesterone is preferred over older synthetic progestins for its more favorable safety profile. Local vaginal estrogen is considered very low risk due to minimal systemic absorption.

Can I take HRT if I have a family history of breast cancer?

A family history of breast cancer is not an automatic contraindication to HRT. It’s a factor your provider will consider alongside your full picture — the type of HRT, your age, timing of menopause, symptom severity, and other risk factors. Many people with a family history of breast cancer use HRT safely. This is exactly the kind of nuanced conversation a knowledgeable provider should have with you.

Do I need a uterus to take HRT?

No. HRT is for anyone experiencing menopause, regardless of anatomy. If you have a uterus and take systemic estrogen, you’ll also need progesterone to protect the uterine lining. If you don’t have a uterus (e.g. due to hysterectomy), you can typically take estrogen alone.

Can HRT help with mood and anxiety?

Yes. Mood changes, irritability, anxiety, and changes in concentration in perimenopause are often hormonally driven — estrogen affects serotonin and dopamine pathways directly. HRT addresses the underlying hormonal cause rather than layering a psychiatric medication on top of a hormonal problem. For some people, treating menopause with HRT resolves mood symptoms entirely. Others may benefit from both HRT and mental health support.

Can HRT help with hot flashes? 

Yes — HRT is the single most effective treatment for hot flashes and night sweats (vasomotor symptoms). Most people notice significant improvement within a few weeks of starting. For people who can't or prefer not to use HRT, non-hormonal options like Veozah (fezolinetant), low-dose SSRIs, or gabapentin can also help, but HRT remains the gold standard. Transdermal and oral estrogen are both effective; your clinician will help determine the best route based on your full health picture.

Can HRT help with sleep?

Yes. Sleep disruption during perimenopause and menopause is often driven by a combination of night sweats, hormonal shifts affecting sleep architecture, and increased anxiety — all of which HRT can address. By reducing night sweats and stabilizing the hormonal fluctuations that fragment sleep, many people see meaningful improvement. If sleep issues persist after starting HRT, that's worth flagging with your clinician — progesterone in particular has mild sedative properties and is often taken at bedtime for this reason. Sleep disruption that doesn't respond to HRT may have other contributing factors worth evaluating.

Does HRT help with bone health?

Yes, significantly. Estrogen plays a key role in maintaining bone density. The accelerated bone loss that occurs in the years around menopause is one of the major long-term health risks of estrogen decline. HRT is one of the most effective ways to preserve bone density and reduce fracture risk. For people who are at elevated risk of osteoporosis, this is worth factoring into the HRT conversation beyond just symptom relief.

How long does it take for HRT to work?

Most people notice improvement in hot flashes and night sweats within a few weeks. Mood and sleep improvements often follow. Genitourinary symptoms, particularly vaginal dryness, may take 2–3 months to fully respond. If you haven’t noticed improvement after 3 months, the dose or formulation may need adjustment — that’s a normal part of the process, not a sign that HRT isn’t working for you.

Do I need labs before starting HRT?

Labs are not required to start HRT. Your clinician may recommend baseline bloodwork depending on your health history — to check thyroid, cholesterol, or other factors — but a normal lab panel is not a prerequisite for treatment. Your symptoms and medical history are what matter most.

What’s the difference between HRT and bioidentical hormones?

Bioidentical hormones are chemically identical to hormones produced by your body. Many FDA-approved HRT formulations — including oral micronized progesterone (Prometrium) and estradiol patches, gels, and creams — are bioidentical. The term is sometimes used to describe compounded custom formulations, which are not FDA-regulated and vary in consistency and dosing accuracy. FOLX prescribes FDA-approved formulations.

‍